Dr. Helfand on how genomic testing provides real-time status of prostate tumor
Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how genomic testing is a great tool for identifying “what is going on in the tumor ‘right now.’”
Related Articles
FDA approves NMIBC treatment nogapendekin alfa-inbakicept/BCG
The median duration of CR in those who experienced a response to treatment was 26.6 months (95% CI, 9.9-not reached [NR]).
Experts develop guide on online tools to reduce costs of urologic drugs
“At a time when patients are increasingly concerned about prescription drugs, this information will provide a useful starting point for making essential medications as affordable…
Dr. Haile discusses medical management of BPH
“Alpha-blockers are often, for patients, the first line of treatment because they help quickly relax the smooth muscles in the bladder and the prostate,” says…
Dr. Wolf on the CVAC System for steerable ureteroscopic renal evacuation
“I cannot overstate the impact of this device on my management of kidney stone patients,” says J. Stuart Wolf, Jr., MD, FACS.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
“This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who…
Urologist encourages consideration of early apical release HoLEP technique
“For those who do enucleations, I think I would encourage people to highly consider adopting an apical release technique if they haven’t,” says Daniel J.…
Dr. Pienta on the evolving paradigm of PSMA-PET imaging
“The advance of PSMA imaging has put an emphasis on multidisciplinary care,” says Kenneth J. Pienta, MD.
212Pb SPECT/CT imaging shows initial benefit, feasibility in mCRPC
“In the future, this imaging technique can help to streamline the drug development process, driving conviction in the agents we bring to larger scale trials,”…
FDA accepts IND application for UGN-103 in NMIBC
The IND will initiate the launch of a phase 3 study to explore the safety and efficacy of UGN-103 in patients with low-grade, intermediate-risk NMIBC.
Clinical trial program of nadofaragene firadenovec in NMIBC expands
The 3 new additional studies are the ABLE-22, ABLE-32, and ABLE-42 clinical trials.